Examkin

Soru

Zorluk: ZorInfectious Diseases

A 52-year-old woman is hospitalized for induction chemotherapy for acute myeloid leukemia. On hospital day 12, she develops a new-onset fever of 38.7∘C38.7^\circ\text{C} (101.7∘F101.7^\circ\text{F}). Her blood pressure is 118/74 mm Hg, pulse is 98/min, and respirations are 16/min. Physical examination reveals no focal source of infection, and the exit site of her right internal jugular central venous catheter is clean without erythema or induration. Laboratory studies show an absolute neutrophil count of 150/mm3150/\text{mm}^3. She is hemodynamically stable and appears fatigued.

Arrange the following steps in the most appropriate chronological sequence for the management of this patient's neutropenic fever.

  1. 1Obtain blood cultures from the central venous catheter and a peripheral vein.
  2. 2Initiate empiric intravenous monotherapy with an antipseudomonal beta-lactam (e.g., cefepime).
  3. 3Maintain the current antimicrobial regimen and reassess clinical status at 48 to 72 hours.
  4. 4Add empiric intravenous antifungal therapy for persistent fever after 4 to 7 days.

Cevap

The correct chronological sequence for managing high-risk neutropenic fever is: 1) Obtain blood cultures (central and peripheral), 2) Initiate empiric antipseudomonal beta-lactam therapy, 3) Reassess clinical response at 48-72 hours without prematurely changing antibiotics, and 4) Add empiric antifungal therapy if fever persists after 4-7 days.
The standard sequence for managing high-risk febrile neutropenia begins with obtaining appropriate diagnostic cultures (blood, urine, sputum if indicated) before giving antibiotics. This is immediately followed by broad-spectrum antipseudomonal monotherapy. Because time to defervescence can be up to a week, the patient is observed for 48-72 hours before considering any changes to the antibacterial regimen, provided they remain hemodynamically stable. Finally, if the fever persists beyond 4 to 7 days of broad-spectrum antibacterial coverage, empiric antifungal therapy is added to cover unrecognized fungal pathogens.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation.
The patient has high-risk febrile neutropenia (ANC < 500/mm3500/\text{mm}^3, fever > 38.3∘C38.3^\circ\text{C}) without hemodynamic instability or catheter-site infection.
This determines the urgency and scope of the required empiric antimicrobial coverage.
2
Determine the immediate initial intervention.
Blood cultures must be drawn from both the central line and a peripheral vein before administering any antibiotics.
Administering antibiotics prior to drawing cultures rapidly sterilizes the blood, preventing the identification of the pathogen and hindering later targeted therapy.
3
Select the appropriate initial empiric antibiotic.
Monotherapy with an antipseudomonal beta-lactam (e.g., cefepime, meropenem, or piperacillin-tazobactam) is indicated.
Broad-spectrum coverage including Pseudomonas is universally required. MRSA coverage (vancomycin) is withheld initially because there is no hypotension, pneumonia, or catheter-site erythema.
4
Determine the short-term follow-up strategy.
Maintain the current regimen and reassess the patient at 48 to 72 hours.
Prematurely altering antibiotics before allowing time for clinical response or culture results promotes antibiotic resistance and increases the risk of medication toxicity.
5
Identify the threshold for adding antifungal coverage.
Add an echinocandin or mold-active azole only if the fever persists beyond 4 to 7 days.
Prolonged neutropenic fever despite broad-spectrum antibacterials carries a high probability of occult invasive fungal infection (e.g., Candida, Aspergillus).

Anahtar Kavram

Management algorithm for high-risk neutropenic fever.

Alternatif Yöntem

While monotherapy with an antipseudomonal beta-lactam is standard, patients presenting with hemodynamic instability or septic shock should receive dual antipseudomonal coverage (e.g., beta-lactam plus an aminoglycoside) and immediate MRSA coverage (vancomycin) as their initial step.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru